A Phase II Study of ZD 1839 (NSC 715055) for Patients With First Relapse Glioblastoma Multiforme
OBJECTIVES:
- Determine the activity of ZD 1839 in patients with glioblastoma multiforme in first
relapse.
- Determine the pharmacokinetics and toxicity of this drug in these patients.
- Assess the relationship between epidermal growth factor receptor status in these
patients and activity of this drug.
OUTLINE: Patients receive oral ZD 1839 once daily. Courses repeat every 28 days in the
absence of disease progression or unacceptable toxicity.
Patients are followed for at least 6 months.
PROJECTED ACCRUAL: A total of 53 patients will be accrued for this study within 12-18
months.
Interventional
Primary Purpose: Treatment
Henry S. Friedman, MD
Study Chair
Duke University
United States: Federal Government
2421
NCT00016991
June 2001
April 2005
Name | Location |
---|---|
Duke Comprehensive Cancer Center | Durham, North Carolina 27710 |